Celltrion Healthcare Co., Ltd.
091990
Classement en actions
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Prix de l'action
$57.75
Dernière synchronisation: 2024-01-11
Capitalisation boursière
$9.42B
Changement (1 jour)
-0.25%
Changement (1 an)
0.00%
Pays
KR
Échange Celltrion Healthcare Co., Ltd. (091990)
Catégorie
Healthcare
Ratio P/B pour Celltrion Healthcare Co., Ltd. (091990)
Ratio P/B au October 2026 TTM : 5.94
Selon les derniers rapports financiers et le cours de l'action de Celltrion Healthcare Co., Ltd., le ratio cours/valeur comptable actuel (TTM) est 5.94. À la fin de 2021, le ratio P/B était de 6.21.
Historique du ratio P/B pour Celltrion Healthcare Co., Ltd. de 2014 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 5.94 | 32.24% |
| 2022 | 4.49 | -27.70% |
| 2021 | 6.21 | -15.82% |
| 2020 | 7.38 | -12.83% |
| 2019 | 8.46 | -1.92% |
| 2018 | 8.63 | 5.42% |
| 2017 | 8.19 | -50.80% |
| 2016 | 16.64 | 27.60% |
| 2015 | 13.04 | 10,587.95% |
| 2014 | 0.12 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | 5.28% |
US
|
|
| 13.2547 | 123.23% |
US
|
|
| 4.4521 | -25.02% |
AU
|
|
| 6.3632 | 7.17% |
NL
|
|
| 3.2932 | -44.54% |
BE
|
